



Staff Contact: Chloe Surinak
International Society for Biological Therapy of Cancer
555 E. Wells St., Suite 1100, Milwaukee, WI 53202
Phone: 414-271-2456 ~ Fax: 414-276-3349
Email: csurinak@isbtc.org ~ Website: www.isbtc.org

NOTE: Members of the media are encouraged to attend the iSBTc Workshop, Annual Meeting, and Hot Topics Symposium free of charge by presenting their press credentials at the iSBTc registration desk at the Gaylord National Hotel, National Harbor, MD (Washington, D.C.). More information on the programs below can be found on the iSBTc website, www.isbtc.org.

MORE HOPE FOR CANCER VICTIMS: iSBTc PRESENTS THE PROMISE OF IMMUNOTHERAPY & BIOLOGICAL THERAPY

MILWAUKEE--- There are exciting new breakthroughs in cancer treatment and they are happening in immunotherapy/biological therapy. For 25 years, the International Society for Biological Therapy of Cancer (iSBTc) has fostered research with immunotherapy/biological therapy for cancer treatment. Its members have pioneered the science of using the body's own immune system to fight cancer. iSBTc will feature these pioneers and innovations at its **24th Annual Meeting and Workshop on Immunologic Biomarkers in Cancer** being held October 28-31, 2009 at the Gaylord National Hotel in Washington, D.C.

iSBTc's **Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer** on October 28 is the culminating event of months of work by leading experts, global partnering organizations and collaborative programs. It is an interactive program that assembles these leading experts and global organizations in the field to discuss and determine best practices and standards related to the use of immunologic biomarkers such as:

- * protocol for the collection and storage of clinical samples
- * minimum quality standards for laboratories developing immunologic biomarkers
- * standards for the reporting of immunologic results
- * key measures of potential potency

Participating Organizations:

Association for Immunotherapy of Cancer (CIMT)
Biotherapy Development Association (BDA)
Cancer Vaccine Consortium (CVC) of the Cancer Research Institute (CRI)
Food and Drug Administration (FDA)
Italian Network for Tumor Biotherapy (NIBIT)
Japanese Society of Cancer Immunology (JSCI)
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Nordic Center for Development of Antitumour Vaccines (NCV-network)

The **iSBTc 24th Annual Meeting** will gather the leading experts in cancer immunotherapy and feature multiple sessions with over 40 speakers highlighting innovative therapies which have applications across many types of cancer such as melanoma, breast, prostate, kidney, lung and leukemia.

Among those scheduled to speak are:

Mark M. Davis, PhD - *Stanford University School of Medicine*
Isaiah J. Fidler, DVM, PhD - *MD Anderson Cancer Center*
Steven A. Rosenberg, MD, PhD - *National Cancer Institute*

In sessions such as:

Adoptive Transfer
Enhancing Cancer Vaccines
Targeted Therapeutics & Biological Therapy

iSBTc received a record number of abstracts representing science from 26 countries for presentation at the 24th Annual Meeting and the Biomarkers Workshop has received record registration as well, both testifying to the global excitement and vitality in cancer immunotherapy research.

This renewed excitement may be due, in part to clinical successes in cancer immunotherapy. Successes which will be highlighted in iSBTc's special **"Hot Topic Symposim: Positive Immunotherapy Clinical Trial Outcomes"** being held immediately following the Annual Meeting on October 31. Data on positive randomized Phase III trials for lymphoma, melanoma and prostate cancer will be featured.

iSBTc has been driving innovation in the field of immunotherapy/biological therapy for cancer for 25 years and continues to be the meeting place where thought-leaders and innovators discuss and develop future cancer treatment for the millions of people stricken by cancer worldwide.

Founded in 1984, the International Society for Biological Therapy of Cancer (iSBTc) is a non-profit organization of clinicians, researchers, students, post-doctoral fellows, and allied health professionals dedicated to improving cancer patient outcomes by advancing the development and application of biological therapy/immunotherapy through interaction, innovation and leadership. For more information about the Society, please visit www.isbtc.org.

###